Better Buy: Vertex Pharmaceuticals vs. CRISPR
Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) each have their own strengths. Vertex has developed a blockbuster portfolio of cystic fibrosis (CF) treatments. CRISPR is working on gene-editing treatments for a variety of serious diseases. These two companies have even joined forces for one major program. So which one of these innovative biotech players makes a better buy right now? Let's find out.
Image source: Getty Images.
Adria Cimino (Vertex): I like Vertex Pharmaceuticals for its market leadership today in CF, and its potential to bring blockbusters in other treatment areas to market in the future. First, let's look at today. The company brings in billions of dollars in revenue and profit annually through sales of four CF drugs. And the biggest threat to these drugs is actually a candidate that Vertex has in development. So, it doesn't look like another company will unseat Vertex any time soon. Vertex has even said its leadership likely will last through at least the late 2030s.
Source Fool.com
